Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer
Abstract
Aim: STING agonists in immunotherapy show great promise and are currently in clinical trials. Combinations of STING agonists with other therapies remain underexplored. This study aimed to combine STING agonist-mediated immunotherapy with photodynamic therapy to treat breast cancer. Methods: STING agonist (ADU-S100)-functionalized porphyrin-based nanoparticles (NP-AS) were prepared and their antitumor properties in terms of cell apoptosis/necrosis and immune activation in triple-negative breast cancer were evaluated. Results: NP-AS induced tumor cell apoptosis/necrosis, activated the innate immune response and exhibited useful antitumor effects. Conclusion: NP-AS effectively treated breast cancer.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 293(2), 247–269 (2016).
- 2. . Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer. Proc. Natl Acad. Sci. USA 117(30), 17543–17550 (2020).
- 3. . Cancer statistics, 2015. CA Cancer J. Clin. 65(1), 5–29 (2015).
- 4. . Clinical applications for targeted therapy in bladder cancer. Urol. Clin. North Am. 32(2), 239–246 (2005).
- 5. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat. Nanotechnol. 16(11), 1260–1270 (2021). • The study explained the potential of cyclic dinucleotide STING gene agonists in the immunotherapy of cancer.
- 6. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science 367(6480), eaau0810 (2020).
- 7. . The cancer immunotherapy revolution. Science 359(6382), 1344–1345 (2018).
- 8. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep. 11(7), 1018–1030 (2015).
- 9. cGAS-STING, an important pathway in cancer immunotherapy. J. Hematol. Oncol. 13(1), 81 (2020).
- 10. Insights on the cGAS-STING signaling pathway during herpesvirus infections. Front. Immunol. 13, 931885 (2022).
- 11. Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy. Nano Lett. 20(4), 2246–2256 (2020).
- 12. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat. Nanotechnol. 14(3), 269–278 (2019).
- 13. . Prospects for combining immune checkpoint blockade with PARP inhibition. J. Hematol. Oncol. 12(1), 98 (2019).
- 14. STING promotes the growth of tumors characterized by low antigenicity via IDO activation. Cancer Res. 76(8), 2076–2081 (2016).
- 15. Engineered nanovaccine targeting Clec9a+ dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist. Nano Lett. 21(23), 9939–9950 (2021). • The study revealed the importance of activating dendritic cells in STING agonist-based cancer immunotherapy.
- 16. . Nanomedicinal delivery of stimulator of interferon genes agonists: recent advances in virus vaccination. Nanomedicine 15(29), 2883–2894 (2020).
- 17. STINGel: controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy. Biomaterials 163, 67–75 (2018).
- 18. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat. Biomed. Eng. 5(5), 455–466 (2021).
- 19. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Sci. Adv. 6(35), eabc3646 (2020).
- 20. Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. Nat. Biomed. Eng. 3(9), 706–716 (2019).
- 21. Smart nanovesicle-mediated immunogenic cell death through tumor microenvironment modulation for effective photodynamic immunotherapy. ACS Nano 14(1), 620–631 (2020). •• The study revealed the advantages of combining photodynamic therapy with cancer immunotherapy.
- 22. Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat. Commun. 10(1), 3199 (2019).
- 23. ER-targeting PDT converts tumors into in situ therapeutic tumor vaccines. ACS Nano 16(6), 9240–9253 (2022).
- 24. A peptide-AIEgen nanocomposite mediated whole cancer immunity cycle-cascade amplification for improved immunotherapy of tumor. Biomaterials 285, 121528 (2022).
- 25. . The importance of exosomal PDL1 in tumor immune evasion. Nat. Rev. Immunol. 20(4), 209–215 (2020).
- 26. Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. Cancer Res. 82(18), 3291–3306 (2022).
- 27. . Crossing the blood–brain barrier. Nat. Rev. Drug Discov. 20(10), 740 (2021).
- 28. . Approaches to treat immune hot, altered and cold tumors with combination immunotherapies. Nat. Rev. Drug Discov. 18(3), 197–218 (2019).
- 29. Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumor growth and metastases in mice. Nat. Commun. 10(1), 2025 (2019).
- 30. Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano 12(12), 12096–12108 (2018).
- 31. A synergistic cancer immunotherapy nano-system for preventing tumor growth. Chem. Eng. J. 380, 122472 (2020).
- 32. Chlorin-based nanoscale metal-organic framework systemically rejects colorectal cancers via synergistic photodynamic therapy and checkpoint blockade immunotherapy. J. Am. Chem. Soc. 138(38), 12502–12510 (2016).
- 33. . Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat. Commun. 7, 13193 (2016).
- 34. Established T cell-inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1 pathway blockade. Cancer Immunol. Res. 4(12), 1061–1071 (2016).
- 35. . Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1–10 (2013).
- 36. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc. Natl Acad. Sci. USA 113(46), E7240–E7249 (2016).
- 37. . Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors. Nat. Commun. 10(1), 1899 (2019).
- 38. Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study. Cancer Immunol. Immunother. 69(6), 1131–1140 (2020).
- 39. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat. Commun. 10(1), 3349 (2019).
- 40. Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. Nanomedicine 15(1), 77–92 (2020).
- 41. . A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175(2), 313–326 (2018).
- 42. Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events. Proc. Natl Acad. Sci. USA 119(29), e2205378119 (2022).
- 43. Expandable immunotherapeutic nanoplatforms engineered from cytomembranes of hybrid cells derived from cancer and dendritic cells. Adv. Mater. 31(18), 1900499 (2019).